Genmab A/S

GMAB

DK0010272202

Biotechnology & Medical Research

Market Closed - Nasdaq Copenhagen Other stock markets 08:50:00 10/07/2025 pm IST			5-day change	1st Jan Change
1,394.50 ^DKK	+1.68%		+7.60%	-6.57%

01/07	Genmab Announces Changes to Its Executive Committee	CI
01/07	Genmab's Chief Legal Officer Steps Down; Successor Named	MT

Genmab Says Japan Approves Tivdak for Cervical Cancer

Published on 27/03/2025 at 18:29, updated on 27/03/2025 at 18:30

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Genmab A/S

Genmab Announces Changes to Its Executive Committee	01/07	CI
Genmab's Chief Legal Officer Steps Down; Successor Named	01/07	MT
UBS Lowers Price Target for Genmab to 2,500 Danish Kroner, Reiterates Buy Recommendation	25/06	FW
Genmab A/S, Q1 2025 Earnings Call, May 08, 2025	17/06
Genmab Says Experimental Combination Trial Shows High Response Rates in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma	16/06	MT
Genmab's Epcoritamab Combination Shows High Response Rates in Cancer Patients	16/06	MT
Genmab A/S Announces Epcoritamab Investigational Combination Therapy Demonstrates High Response Rates in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (L) Eligible for Autologous Stem Cell Transplantation	15/06	CI
Genmab A/S Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 08:00 AM	09/06
AlphaValue/Baader Europe Keeps Genmab at Buy, Boosts Price Target on Pipeline Strength	09/06	MT
GENMAB : Beaten up share price offers an opportunity	06/06
Genmab's Rina-S shows promising efficacy in difficult-to-treat uterine cancer	03/06	FW
Sector Update: Health Care Stocks End Higher Late Afternoon	03/06	MT
Genmab Says New Trial Data Shows 'Encouraging Anti-Tumor Activity' for Rinatabart Sesutecan	03/06	MT
Genmab A/S Announces Investigational Rinatabart Sesutecan (Rina-S) Demonstrates Encouraging Anti-Tumor Activity Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL-01 Trial	03/06	CI
RBC lowers target price for Genmab to DKK 2,000 (2,300), reiterates outperform rating - BN	30/05	FW
RBC Cuts Price Target on Genmab to DKK2,000 From DKK2,300, Keeps Outperform Rating	29/05	MT
Deutsche Bank lowers target price for Genmab to DKK 1,750 (1,900), reiterates buy recommendation	23/05	FW
Redburn lowers target price for Genmab to DKK 2,700 (2,750), reiterates buy recommendation - BN	23/05	FW
Genmab A/S to Present New and Updated Results from Its Robust Epcoritamab (Epkinly®) Development Program At the 2025 European Hematology Association Congress	14/05	CI
UBS lowers target price for Genmab to DKK 2,600 (2,700), reiterates buy recommendation	12/05	FW
GENMAB : Mixed Q1; guidance maintained	10/05
Nordea Bank Upgrades Genmab to Buy	09/05	MT
Nykredit lowers target price for Genmab to DKK 1,750 (2,000), reiterates buy recommendation - BN	09/05	FW
Nordea raises Genmab to buy (hold), target price SEK 2,009	09/05	FW
Goldman Sachs raises target price for Genmab to DKK 1,785 (1,764), reiterates neutral rating - BN	09/05	FW

Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows: - royalties (80.6%); - income from research and development (9.3%); - other (10.1%): primarily income from partnership agreement. At the end of 2024, the group had a portfolio of more than 20 products in clinical development phase and 20 in preclinical development phase. Net sales are distributed geographically as follows: Denmark (91.9%), the United States (4.2%) and Japan (3.9%).

Employees

2,638

Sector

Biotechnology & Medical Research

Calendar

07/08 - Q2 2025 Earnings Release

More about the company